other-cancer

Key cancer-causing pathway in oral squamous cell carcinoma identified—Notch1/DLL4 drives disease.

Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, and Notch signaling is frequently altered in it. Using transgenic animal models, advanced imaging, and next-generation sequencing, this study mapped Notch pathway dysregulation in OSCC development and progression.

Dan Manning

Dan Manning

— 1 min read
Share
Key cancer-causing pathway in oral squamous cell carcinoma identified—Notch1/DLL4 drives disease.

Key cancer-causing pathway in oral squamous cell carcinoma identified—Notch1/DLL4 drives disease.

Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, and Notch signaling is frequently altered in it. Using transgenic animal models, advanced imaging, and next-generation sequencing, this study mapped Notch pathway dysregulation in OSCC development and progression.

Notch1 and Delta-like-4 (DLL4) showed specific expression in malignant tissue, while Jagged1 was downregulated—a distinctive pattern. Transcriptomic analyses confirmed Notch pathway disruption linked to undifferentiated cancer cell identity. Pharmacological Notch inhibition significantly impaired cancer cell motility.

The Notch1/DLL4 axis appears to be a central oncogenic driver in OSCC, making it a candidate for targeted therapeutic intervention.

Key Findings

  • Notch1 and DLL4 specifically expressed in malignant OSCC tissue vs. normal
  • Jagged1 downregulated in OSCC—specific Notch pathway alteration
  • Transcriptomic signature of undifferentiation associated with Notch dysregulation
  • Pharmacological Notch inhibition significantly impaired OSCC cell motility
  • Notch1/DLL4 axis identified as central oncogenic driver in OSCC

Implications

The Notch1/DLL4 signaling axis is a potential therapeutic target in OSCC. Notch inhibitors (gamma-secretase inhibitors, anti-DLL4 antibodies) already in development for other cancers could be evaluated in OSCC. This provides a mechanistic framework for targeted therapy development.

Caveats

Preprint (bioRxiv); not yet peer-reviewed; abstract-only. Transgenic animal models may not fully recapitulate human OSCC. Pharmacological Notch inhibition is broadly toxic—selective targeting needed. Translational gap remains significant.

Source: bioRxiv — 2026-04-12

Read more